Zafgen to Present at the JMP Securities Life Sciences Conference
13 Juin 2019 - 10:15PM
Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical
company leveraging its proprietary knowledge of MetAP2 systems
biology to develop novel therapies for patients affected by a range
of metabolic diseases, announced today that Jeffrey Hatfield, Chief
Executive Officer of Zafgen, Inc. is scheduled to present at the
JMP Securities Life Sciences Conference on Thursday, June 20, 2019,
at 10:30 a.m. ET.
A live audio webcast and replay of the presentation will be
available through the Events and Presentations page of the
Investors section of the Company's website (www.zafgen.com) for 90
days following the conclusion of the live event.
About Zafgen
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical
company leveraging its proprietary MetAP2 biology platform to
develop novel therapies for patients affected by complex metabolic
diseases. Zafgen has pioneered the study of MetAP2 inhibitors in
both common and rare metabolic disorders and is currently advancing
programs for type 2 diabetes, Prader-Willi syndrome and liver
diseases. Learn more at www.zafgen.com.
Media/Investor Relations Contacts:Zafgen, Inc.
Patricia Allen Chief Financial Officer 617-648-9792
MediaKrystle GibbsTen Bridge Communications
krystle@tenbridgecommunications.com 508-479-6358
InvestorsJohn
WoolfordWestwickejohn.woolford@westwicke.com443-213-0506
Zafgen (NASDAQ:ZFGN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Zafgen (NASDAQ:ZFGN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Zafgen Inc (NASDAQ): 0 recent articles
Plus d'articles sur